UBE2N
MOLECULAR TARGETubiquitin conjugating enzyme E2 N
UBE2N (ubiquitin conjugating enzyme E2 N) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting UBE2N
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | naringin | 1.61 | 4 |
| 2 | Chlorhexidine | 1.61 | 4 |
| 3 | Perphenazine | 1.61 | 4 |
| 4 | Sphingosine | 1.61 | 4 |
| 5 | Resveratrol | 0.69 | 1 |
| 6 | Sertraline | 0.69 | 1 |
| 7 | Astemizole Antihistamine drug now withdrawn from | 0.69 | 1 |
| 8 | Canrenone | 0.69 | 1 |
| 9 | Thioridazine | 0.69 | 1 |
About UBE2N as a Drug Target
UBE2N (ubiquitin conjugating enzyme E2 N) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented UBE2N interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
UBE2N inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.